C1 Esterase Inhibitor (Cinryze)

Cinryze is covered for prophylaxis of HAE attacks (FDA‑approved) and for treatment of acute HAE attacks (compendial) in patients with Type I or II C1‑INH deficiency, and is not authorized if diagnostic criteria or required specialist involvement are not met. Coverage requires baseline labs showing functional C1‑INH <50% and low serum C4, prescription by or in consultation with an allergist/immunologist or HAE specialist, 12‑month approvals with reauthorization contingent on documented clinical benefit, and dosing limits (≥12 years: ≤2,500 U IV and ≤100 U/kg, no more than twice weekly; ages 6–11: ≤1,000 U IV, no more than twice weekly; doses ≥3 days apart).

"Cinryze is indicated for prophylaxis against Hereditary Angioedema (HAE) attacks."

Sign up to see full coverage criteria, indications, and limitations.